Labcorp, a global leader of innovative and comprehensive laboratory services, announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable answers when treating suspected fentanyl exposure in emergency departments, hospitals and clinics.

Fentanyl exposure remains a concern across acute care and clinical settings. Labcorp data show that between 2024 and 2025, approximately 4 per cent of pre-employment screenings tested positive for fentanyl, and nearly 10 per cent of patients receiving opioid use disorder treatment tested positive. Recent guidance from the Association for Diagnostics and Laboratory Medicine (ADLM) also highlights the importance of reliable screening tools in emergency care, particularly as synthetic opioids like fentanyl become more prevalent.